Our novel PDOX procedure converts hematological malignancies into an orthotopic model for robust efficacy studies.
LIDE has established over 20 hematological malignancy patient-derived orthotopic xenografts (PDOXs) including AML, ALL, multiple myeloma, and different kinds of lymphoma.
Model ID |
Sex |
Age |
PDX pathology |
PDX s.c. |
PDOX i.f. |
LD1-0041-362047 |
Male |
51 |
ALL |
Y |
Y |
LD1-0041-362073 |
Male |
64 |
ALL |
Y |
Y |
LD1-0041-362356 |
Male |
53 |
ALL |
Y |
Y |
LD1-0041-362478 |
Male |
15 |
ALL |
Y |
Y |
LD1-1041-362519 |
Female |
38 |
ALL |
N/A |
Y |
LD1-0041-362021 |
Male |
32 |
ALL |
N/A |
Y |
LD1-0040-361280 |
Female |
38 |
AML |
Y |
Y |
LD1-0040-361293 |
Female |
61 |
AML |
Y |
Y |
LD1-0040-362349 |
Male |
23 |
AML |
Y |
Y |
LD1-0040-362384 |
Male |
59 |
AML |
N/A |
Y |
LD1-0040-362030 |
Female |
56 |
AML |
N/A |
Y |
LD1-0040-361780 |
Male |
49 |
AML |
N/A |
Y |
LD1-0040-362224 |
Male |
75 |
AML |
N/A |
Y |
LD1-0040-362369 |
Male |
57 |
AML |
Y |
Y |
LD1-0040-362393 |
Female |
57 |
AML |
Y |
Y |
LD1-0040-362499 |
Male |
68 |
AML |
N/A |
Y |
LD1-0040-362575 |
Female |
31 |
AML |
Y |
Y |
LD1-0026-362219 |
Male |
24 |
Burkitt's lymphoma |
Y |
N/A |
LD2-0026-200614 |
Male |
/ |
CLL transit to DLBCL |
Y |
N/A |
LD1-0026-362314 |
Male |
51 |
Mantle cell lymphoma |
Y |
N/A |
LD1-0029-361915 |
Male |
62 |
Multiple myeloma |
Y |
N/A |
LD1-0029-361847 |
Male |
54 |
Multiple myeloma |
Y |
N/A |
LD1-0006-370728 |
Male |
68 |
Multiple myeloma |
Y |
N/A |
Methodology
- Tumor cell suspension generated from fresh bone marrow biopsy or peripheral blood sample.
- Suspensions are then inoculated into NCG mice intrafemorally.
- FACS analysis is performed periodically using whole blood from the mice to determine engraftment.
- Mice spleen, as the tumor source, are isolated for PDOX cryopreservation for further in vivo efficacy studies.
Fig. Schematic of PDOX process for hematological malignancies